Literature DB >> 21824802

Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.

Yoram Cohen1, Nitza Goldenberg-Cohen, Bruria Shalmon, Tali Shani, Shirley Oren, Ninette Amariglio, Olga Dratviman-Storobinsky, Anna Shnaiderman-Shapiro, Ran Yahalom, Ilana Kaplan, Abraham Hirshberg.   

Abstract

The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma (AKT) viral oncogene pathway is involved in regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation, and cell growth. Mutations in the genes associated with the PI3K/AKT pathway including PI3K, AKT, RAS and PTEN, are infrequently found within head and neck squamous cell carcinoma and more specifically are rarely reported in oral squamous cell carcinoma (OSCC) cases. We aimed to investigate the frequency of mutations in AKT1, PTEN, PIK3CA, and RAS (K-RAS, N-RAS, H-RAS) genes in 37 cases of oral squamous cell carcinoma (OSCC). Mutational analysis of PTEN, RAS, PIK3CA and AKT genes was performed using chip-based matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry and by direct sequencing. The only gene mutated in our series was the PIK3CA. Missense mutations of the PIK3CA gene were found in 4 of our cases (10.8%); no correlation has been found with oral location, stage and survival. The absence of mutations in AKT1, PTEN, and RAS genes in the present study is in accordance with previous studies confirming that these genes are rarely mutated in OSCC. Our data confirm that PIK3CA is important to OSCC tumorigenesis and can contribute to oncogene activation of the PIK3CA/AKT pathway in OSCC. The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824802     DOI: 10.1016/j.oraloncology.2011.07.013

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  18 in total

Review 1.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

2.  Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.

Authors:  Xiaoxiao Wan; Xian Li; Junyan Yang; Wei Lv; Qiming Wang; Ying Chen; Yong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

Review 4.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

5.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

Review 6.  Genetic alterations and clinical dimensions of oral cancer: a review.

Authors:  Keerthana Karunakaran; Rajiniraja Muniyan
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

7.  PIK3CA and p53 Mutations Promote 4NQO-Initated Head and Neck Tumor Progression and Metastasis in Mice.

Authors:  Darío García-Carracedo; Yi Cai; Wanglong Qiu; Kiyoshi Saeki; Richard A Friedman; Andrew Lee; Yinglu Li; Elizabeth M Goldberg; Elias E Stratikopoulos; Ramon Parsons; Chao Lu; Argiris Efstratiadis; Elizabeth M Philipone; Angela J Yoon; Gloria H Su
Journal:  Mol Cancer Res       Date:  2020-03-09       Impact factor: 5.852

Review 8.  Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.

Authors:  Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-07       Impact factor: 2.503

9.  A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  Tuhina Mazumdar; Lauren A Byers; Patrick Kwok Shing Ng; Gordon B Mills; Shaohua Peng; Lixia Diao; You-Hong Fan; Katherine Stemke-Hale; John V Heymach; Jeffrey N Myers; Bonnie S Glisson; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2014-09-05       Impact factor: 6.261

10.  p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.

Authors:  Wen-Liang Kuo; Marina N Sharifi; Mark W Lingen; Omar Ahmed; Jing Liu; Madhavi Nagilla; Kay F Macleod; Ezra E W Cohen
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.